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Strains of bacterial pathogens that have acquired mutations conferring antibiotic resistance often have a
lower growth rate and are less invasive or transmissible initially than their susceptible counterparts. However,
fitness costs of resistance mutations can be ameliorated by secondary site mutations. These so-called com-
pensatory mutations may restore fitness in the absence and/or presence of antimicrobials. We review literature
data and show that the fitness gains in the absence and presence of antibiotic treatment need not be correlated.
The aim of this study is to gain a better conceptual grasp of how compensatory mutations with different fitness
gains affect evolutionary trajectories, in particular reversibility. To this end, we developed a theoretical model
with which we consider both a resistance and a compensation locus. We propose an intuitively understandable
parameterization for the fitness values of the four resulting genotypes (wild type, resistance mutation only,
compensatory mutation only, and both mutations) in the absence and presence of treatment. The differential
fitness gains, together with the turnover rate and the mutation rate, strongly affected the success of antibac-
terial treatment, reversibility, and long-term abundance of resistant strains. We therefore propose that
experimental studies of compensatory mutations should include fitness measurements of all possible genotypes
in both the absence and presence of an antibiotic.
The global rise of antimicrobial resistance in bacteria, com-
bined with the decreasing number of innovative antibacterial
agents, has led to warnings that we may soon lose our ability to
treat bacterial infections (82). This spread of strains that are
genetically resistant is occurring despite the fact that resistance
is often costly. When resistance is due to an altered target, this
target might not work as well as its progenitor. Efflux pumps or
bacterial enzymes that modify the antibiotic often lead to met-
abolic costs (1). This fitness loss may be reflected in a reduced
growth rate in vivo (e.g., see reference 51) or in vitro (reviewed
in references 3 and 85), a reduced transmission rate (66), a
higher clearance rate (29), or decreased invasiveness (22) in
the absence of antibiotics. The costs of resistance are among
the most important factors determining both the rate and ex-
tent of resistance emergence (2, 3, 15, 32, 44, 50). In order to
devise strategies to contain antibacterial resistance, we there-
fore need to predict the fitness trajectories (i.e., how the fitness
of a strain will change over time) of resistant strains and to
investigate whether and how resistance may be reversible once
it has emerged.
Antimicrobial-induced killing or growth suppression does
not necessarily increase monotonically with drug concentra-
tion. Therefore, it is not always clear how the MIC and the
growth rate at a defined concentration are correlated. Rather
than making assumptions about the fitness landscape, in the
following material we take the growth rate at therapeutic con-
centrations as a proxy for fitness in the presence of treatment.
In general, the effect of deleterious mutations can be re-
duced by secondary site mutations, so-called compensatory or
suppressor mutations (39, 50, 83). Compensation of costs of
antimicrobial resistance seems to be the rule rather than the
exception and has been found in many bacterial species (9, 10,
12), but also in HIV (6), in fungi (20, 72), and in protozoans
(37, 49). The costs of resistance are usually measured relative
to the corresponding wild-type fitness in the absence of anti-
biotics (4), and compensation is often seen as a process that is
necessary in the absence of antibiotic treatment, when the
resistant bacteria have to compete with their susceptible coun-
terparts (2, 43). Thus, in many studies, the fitness of resistant
compensated strains was measured in competition with wild-
type bacteria and in the absence of antibacterial treatment
(e.g., see references 11, 36, 70, and 73). While competition with
the wild type increases selection pressure on less-fit resistant
microorganisms, antibiotic resistance may—as mentioned
above—also impair the pathogens’ ability to infect and spread,
and thus their general viability. It is therefore conceivable that
these fitness losses also have to be compensated in the pres-
ence of antibiotics to escape extinction. Indeed, compensation
is often referred to as a process that can take place in either the
absence or presence of antibiotics (2, 3, 32, 43, 50). It is com-
monly assumed, however, that compensatory mutations confer
a fitness advantage in both environments (8, 43, 73). In HIV,
compensatory mutations that increase fitness regardless of the
presence of an antiviral have been found (14), while mutations
increasing both fitness and MIC have been found in bacteria
(52, 68). However, only two studies have compared compensa-
tion in the absence and presence of antimicrobial selection pres-
sure in bacteria by use of growth rates (63, 67). In a study by
Paulander et al. (63), many mupirocin-resistant compensated
strains that evolved in the absence of drugs had increased fitness
only in this environment. In analogy to resistance mutations that
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lead to drug dependence (e.g., see reference 69), it is also possible
that some compensatory mutations confer a fitness advantage
only in the presence of treatment, thereby leading to a pseudo-
dependent or dependent phenotype, with organisms growing bet-
ter or only when the respective drug is present (7, 60, 64).
On an epidemiological level, decreasing levels of resistance
after a reduction in selection pressure may be due to two
fundamentally different processes. The prevalent strains may
have lost the resistance gene(s), or unrelated, susceptible
strains may have coincidentally replaced the former strains (2).
Theoretically, the latter is expected to be much more common,
if not the only possibility (2, 42), and the accumulation of
compensatory mutations is one of the barriers to genetic re-
versions. In a setting with a resistance and a compensation
locus, both single-mutant genotypes (i.e., resistance or com-
pensation only) may give a lower fitness than either the wild
type or the resistant-compensated genotype. Therefore, rever-
sion from the resistant-compensated genotype to the wild type
may be impeded by a fitness valley (73). Also, since often more
than one mutation confers resistance, the effective rate of
acquiring a particular resistance mutation may be higher than
the rate of reversion. By the same logic, compensatory muta-
tions are more easily gained than lost (2), and population
bottlenecks arising from transmission (or, in vitro, from serial
passage) can additionally enrich compensated mutants (43).
While these theoretical findings are in agreement with many
epidemiological and experimental studies, genetic reversion to
susceptibility has been described repeatedly, and several ex-
perimental studies describe reversion of clinical isolates after
serial passages without antibiotic in vitro (16, 56, 81). Rever-
sion may be more likely in vivo than in vitro (12) and was also
found within single patients (29, 33, 48, 57, 70).
The aim of this study was to explore whether compensatory
mutations leading to differential fitness gains in the presence
and absence of drugs may explain the divergent findings con-
cerning reversibility. It was therefore necessary to define the
fitness of resistant and resistant compensated bacteria in both
environments. Here we consider the simplest possible genetic
setup of two loci, a resistance and a compensation locus, both
of which are located on the chromosome. We constructed a
model of a single bacterial population that focuses on the
effects of the fitness gains in the two environments and ex-
plores how these—together with other parameters—determine
whether an infection is cleared or the treatment fails. Further-
more, we investigate how the same factors influence whether
reversion can take place after discontinuing drug therapy. Fi-
nally, we study how different degrees of compensation in each
environment influence the dynamics in bacterial populations
during fluctuating selection pressure.
MATERIALS AND METHODS
We consider a single bacterial population and two genetic loci: a resistance and a
compensation locus. Let us denote by nij the number of bacteria of genotype ij in the
population. In this study, i denotes the presence (i  R) or absence (i  ) of
antibiotic resistance, while j denotes the presence (j  C) or absence (j  ) of a
compensatory mutation (see boxes in Fig. 1). Bacterial growth occurs according to
the continuous-time logistic growth model, in which r denotes the maximum growth
rate, d denotes the death rate (kill rate), and K denotes the carrying capacity of the
population (reviewed in reference 54), illustrated by solid arrows in Fig. 1. Unless the
kill rate is zero, the carrying capacity is never reached and a constant population size
is maintained due to a balance of death and growth rather than to a cessation of
replication. Actual replication rates depend on the fitness (wij,A) of bacteria and may
be lower than the maximum, depending on genotype ij and antibiotic treatment A
(treatment or no treatment). Antimicrobial-induced killing or growth suppression
does not necessarily increase monotonically with drug concentration (41, 61; re-
viewed in reference 84). We therefore assume for simplicity that the antibiotic
concentration during one treatment course is high enough to achieve a maximal kill
rate or growth suppression of the wild type, resulting in two drug concentrations:
either zero or therapeutic levels.
The parameterization of the resulting eight fitness values is described in the
following section and summarized in Tables 1 and 2. We approximate mutation
as a first-order process which occurs at rates 3 and 4 at the resistance locus
and at rates 3 and 4 at the compensatory locus (see dashed arrows in Fig. 1).
In this notation, the subscript arrows denote the direction of mutation. For
example, the mutation rate from the wild-type allele to the resistance allele is
3, and the mutation rate from a compensatory allele to a wild-type allele is 4.
For simplicity, we assume that mutations do not occur at both loci simulta-
neously, because the probability of two simultaneous mutations is very low.
In exponentially growing cells, mutations usually occur during replication (46).
Therefore, the rate at which new mutants arise should decrease as the population
approaches carrying capacity or when bacteria are exposed to bacteriostatic
treatment. Yet the fidelity of replication decreases when bacteria enter stationary
FIG. 1. Diagram of model 1. We consider two loci, a resistance and
a compensation locus, resulting in four possible genotypes: wild type
(), resistance mutation only (R), compensatory mutation only
(C), and resistant-compensated genotype (RC). Each genotype is
represented by a box. Strains of all genotypes die with a rate d (see
solid lines leaving the boxes) and replicate depending on their individ-
ual fitness levels in the current environment, wij,A, and a density-
dependent term, D(n), which corresponds to 1 minus the total pop-
ulation size divided by the carrying capacity 1  1Ki, jnij (see
circular arrows). Mutations occur at rates 3 and 4 at the resistance
locus and at rates 3 and 4 at the compensatory locus (see dotted
lines between the boxes). In this notation, the subscript arrows denote
the direction of mutation.
TABLE 1. Parameters used to describe bacterial fitness
Parameter Description
a ............................Antimicrobial activity
cC ..........................Cost of compensatory mutation
cR ..........................Cost of resistance mutation
eR ..........................Efficiency of resistance
eC,no drug ...............Efficiency of compensation in the absence of drug
eC,drug....................Efficiency of compensation in the presence of drug
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phase (reviewed in reference 74) or when antibiotics induce a stress response
(e.g., see reference 19), and mutations may also accumulate during the cell cycle
(46). We therefore used two different approaches to describe mutation: one in
which new mutants are generated depending only on the abundance of the
parental strain and one in which this depends on both the abundance and growth
rate of the parental cells.
With the first assumption (the generation of new mutants depends on the
population size only), the set of differential equations for the numbers of bacteria
of the different genotypes can be stated as follows.
dn
dt  nrw,A1 1K
i,j
nij  nd 3 v3 4nR v4nC
(1)
dnR
dt  nRrwR,A1 1K
i,j
nij  nRd 4 v3 3n v4nRC
(2)
dnC
dt  nC rwC,A1 1K
i,j
nij  nCd 3 v4 4nRC v3n
(3)
dnRC
dt  nRC rwRC,A1 1K
i,j
nij  nRCd 4 v4 3nC v3nR.
(4)
The equations for the second model, where the rise of new mutants depends on
both growth rate and the population size, are given in the supplemental material.
In these two cases, the growth of the cells is assumed to be proportional to
bacterial fitness. Alternatively, high bacterial fitness may also correspond to a low
kill rate, e.g., by better tolerance for an adverse environment, such as resistance
to bactericidals. In this case, the respective fitness values are not multiplied by
the growth rate r, but bacterial killing takes place at the rate nij[r(1  wij)  d]
(see the supplemental material). In the following, we focus on the first model, but
the results obtained were also compared to the second (mutation rates depend
on growth rates) and third (high bacterial fitness corresponds to a low kill rate)
versions of the model. A list of all parameters used in the model and their
standard values are given in Table 2.
The systems of differential equations were solved numerically by using the
lsoda function of the R language for statistical computing (35; www.r-project
.org). The programs are available upon request.
RESULTS
Classification and parameterization. To investigate the ef-
fects of compensation in both the absence and presence of
treatment, it is first desirable to find a suitable parameteriza-
tion for the fitness of bacteria carrying the resistance mutation
alone (R), the compensatory mutation alone (C), both
mutations (RC), or no mutations () in these two environ-
ments.
(i) Parameterization of bacterial fitness. The fitness of the
four genotypes in the absence and presence of antimicrobial
treatment is described using the parameters given in Table 3.
All fitness values are expressed relative to the fitness of wild-
type () bacteria without treatment (Table 1). Susceptible
strains have a high fitness level in the absence of antibiotic
treatment and a very low fitness level in its presence. The
fitness loss upon exposure to antimicrobial agents depends on
the antimicrobial activity (a) of the drug. Strains carrying a
resistance mutation generally have intermediate to high fitness
levels in both environments. The fitness gain during antibac-
terial treatment can be described by the efficiency of the resis-
tance mutation (eR) in reducing the antimicrobial activity (a).
Compared to the wild-type strain in the drug-free environ-
ment, the fitness of resistant mutants in both environments is
often lower. In this case, this fitness cost is incorporated by the
parameter cR. Although the costs of a resistance mutation
sometimes depend on the presence of the antibiotic (e.g., see
reference 69), we assume here for simplicity that they are the
same in both the absence and presence of drug. The compen-
satory mutation ameliorates the cost of resistance for the RC
genotype, and it may do so with different efficiencies, eC,no drug
and eC,drug, in the drug-free and drug-containing environ-
ments, respectively. By definition, the compensatory mutation
on its own (i.e., in the C genotype) does not confer any
protection from the drug, and it is assumed to incur a fitness
cost (cC) independent of the environment.
(ii) Types of compensatory mutations. Using the parameter-
ization explained above (Table 1), one can distinguish three
types of compensation: a type that, as usually assumed,
confers a fitness advantage in both environments (eC,drug 
0, eC,no drug  0) (Fig. 2C), a type that compensates only in
TABLE 2. Fitness values for the four considered genotypes in
absence and presence of antimicrobial treatment
Genotype Fitness in the absenceof drug Fitness in the presence of drug
 1 1  a
C 1  cC (1  a)(1  cC)
R 1  cR 	1  a(1  eR)
(1  cR)
RC 1  cR(1  eC,no drug) 	1  a(1  eR)
	1  cR(1  eC,drug)

TABLE 3. Parameters for model describing bacterial growth
Parameter Description Value (reference[s])
r Maximum growth rate of bacteria 1.3/h (within host growth rate) (26, 59)
N0 Bacterial population size when treatment is initiated 10
5–109a
K Carrying capacity of the population 1010
d Kill rate 0.5r, unless variedb
wij,A Relative fitness of genotype ij, depending on whether antibiotic is
administered (A  1) or not (A  0)
See Table 1
3, 4 Mutation rates at antibiotic resistance locus 10
6 to 1010/h, 2  106 to 1010/division (53)
3, 4 Mutation rates at compensatory locus Unless stated otherwise, 10 (63, 67)
a Symptom onset in bladder infection occurs at 102 CFU/ml (N0  5  104) (80). Bacterial counts in bacteremia are 0.3  103 to 165  103 CFU/ml (N0  1.5 
106 to 8.25  108) (65).
b Assuming bacteriostatic action and zero net growth, this corresponds to a reduction of bacterial load of 0.15/h (2 log within 24 h) for the default value of r  1.3/h
(27).
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the absence of antibiotics (eC,drug  0) (Fig. 2A), and a type
that compensates only in the presence of antibiotics (eC,no drug 
0) (Fig. 2B). One line of reasoning for why such a classification
is useful is as follows. The argument that compensatory muta-
tions arise during therapy and then make reversion difficult or
impossible after discontinuation is valid only if we assume
compensation in both cases. If compensation does not confer
any fitness gain in the presence of treatment, then it is unlikely
to evolve during therapy, even if bacterial counts are very high
and the rate of bacterial killing is low. If the compensatory
mutation leads to increased fitness only in the presence of
treatment, then no fitness valley would hinder reversion.
(iii) Examples from literature data. As mentioned above,
compensatory mutations decreasing viability in the absence of
drug have been found repeatedly in clinical isolates of vanco-
mycin-resistant enterococci (64, 71). In this case, no fitness
valley hinders reversion (Fig. 2B), and in vitro studies showed
that a reversion to the R genotype is possible (24, 79). Sim-
ilarly, compensatory mutations that increase fitness in the ab-
sence of drugs may be costly in the presence of treatment.
Paulander et al. (63) showed that mupirocin-resistant Salmo-
nella enterica serovar Typhimurium strains may acquire com-
pensatory mutations depending on whether they evolved in the
absence or presence of mupirocin. In this study, several lin-
eages of four spontaneous mupirocin resistance mutations
were propagated both in the absence and in the presence of the
antibiotic. The resulting compensatory mutations were identi-
fied, and the growth rates of the mutants were measured in
both the absence and presence of mupirocin. When bacteria
were propagated without antibiotic, the acquired compensa-
tory mutations often decreased fitness in drug-containing me-
dium (corresponding to Fig. 2A), sometimes to the point that
no growth could be observed (see Fig. S2 in the supplemental
material). Pseudoreversion was also observed in mupirocin-
resistant Staphylococcus aureus strains (34). The type of com-
pensatory mutation can be determined by plotting eC,drug
against eC,no drug, as illustrated with the data set from Paul-
ander et al. (Fig. 3). The fitness values from this study were
used to calculate eC,drug and eC,no drug according to the equa-
tions given in Table 1. In this case, the value of eC,drug de-
pended on the selecting environment, whereas the values of
eC,no drug did not show significant differences. For strains that
evolved in the absence of antibiotics, we found a weak negative
correlation between eC,no drug and eC,drug (Pearson’s product-
moment correlation; R2  0.25; P  0.01); for those that
FIG. 2. Types of compensatory mutations. The x axis shows how many mutations the genotype has compared to the wild type. The y axis shows
the replicative fitness compared to that of the wild type. The fitness in the absence of drugs is shown in black, and the fitness in the presence of
antibiotic treatment is shown in red.  denotes the wild type (wt), R the genotype with only the resistance mutation, C the genotype carrying
only the compensatory mutation, and RC the resistant-compensated genotype. Three extreme types of compensation are possible. (A) The
compensatory mutation may be beneficial only in the absence of drugs (eC,no drug  1 and eC,drug  0). (B) Conversely, compensation may occur
only in the presence of treatment (eC,no drug  0 and eC,drug  1). (C) Finally, compensation may have the same efficiency in both environments
(eC,no drug  1 and eC,drug  1). Other parameters take the following values: a  0.9, cC  0.1, cR  0.2, and eR  0.9.
FIG. 3. Compensation in absence versus compensation in presence
of antibiotics. The equations in Table 1 were used to derive eC,no drug
and eC,drug from the data set of Paulander et al. (63). The blue empty
circles indicate resistant compensated strains that evolved in the ab-
sence of drugs, and the red empty triangles indicate resistant compen-
sated strains that evolved in the presence of an antibiotic. The filled
symbols indicate the means with standard deviations.
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evolved in the presence of treatment, we found no correlation
(R2  0.01; P  0.6), which supports the assumption that both
should be treated as independent parameters. In this case,
eC,no drug and eC,drug of some compensatory mutations adopted
values of 1, meaning that they increased fitness more than
only removing the costs of resistance, but without increasing
fitness above wild-type levels. We assume here for simplicity
that resistance has the same cost in the absence and presence
of treatment and that compensatory mutations do not carry
any costs in both environments when paired with a resistance
mutation. Therefore, eC,no drug and eC,drug should be regarded
as measures of the fitness gain in both environments relative to
each other rather than as absolute values.
Theoretical model exploring compensation in bacterial pop-
ulations. (i) Bacterial survival during drug therapy. Whether
a bacterial strain will survive long-term antimicrobial therapy
depends on its ability to replicate under these conditions or to
enter a less-susceptible physiological state (e.g., persisters). In
the following, we assume for simplicity that we have a homo-
geneous population of cells that divide at the same rate (i.e., no
persisters). The RC genotype is the fittest during drug therapy,
so survival will depend on its fitness and thus on values of a, eR,
cR, and eC,drug. Since the bacterial growth rate has to be at least
as high as the kill rate (wr  d) for survival during treat-
ment, the fitness of the RC genotype has to be at least as
high as the bacterial death rate divided by the growth rate,
i.e., wRC  [1  a(1  eR)][1  (1  eC,drug)cR]  d/r.
In Fig. 4, we show for which values of eR, cR, and eC,drug
extinction is inevitable. As expected, with an increasing effi-
ciency of compensation, bacterial survival becomes possible for
a higher cost and a lower efficiency of resistance. However,
even with perfect compensation (eC,drug  1), extinction will
ensue if the efficiency of resistance is not high enough to allow
growth that exceeds the death rate, so eR  1  (r  d)/ra.
Without any compensation and perfect resistance, costs of
resistance that exceed 1  d/r will lead to extinction. This
implies that resistance mutations can be more costly when
antibacterial treatment is suboptimal (i.e., when a is smaller).
Also, the bacterial death rate influences both maximal costs
(cR) and the minimal efficiency of resistance (eR) that allow
survival in the presence of antimicrobial treatment. The higher
the kill rate, the more restrictive the conditions for the out-
growth of resistant bacteria will be. Because we disregard het-
erogeneities in the bacterial population, these predictions are
more qualitative than quantitative.
So far, we have considered only the fitness of the RC geno-
type. Yet when a bacterial population is confronted with an
antibiotic that it has never been exposed to, the RC genotype
may not be present yet, such that the fitness of the R geno-
type becomes important. Although resistance mutations often
preexist, we first illustrate this with an initially homogeneous
wild-type population. In this case, the wild-type population
decreases substantially after treatment initiation (see Fig. S3 in
the supplemental material), before the R and RC genotypes
emerge. Figure 5 shows how the costs of resistance and the
efficiency of compensation (in the presence of treatment) in-
fluenced the minimal total population size (i.e., the population
size at the nadir after treatment is initiated). As expected,
survival did not depend on the efficiency of compensation at
low costs of resistance and thus high R fitness. The higher the
costs of resistance, the more important the fitness of the RC
population became. Apart from the net replication rate of the
individual genotypes, both mutation rate and the population
size when therapy was initiated determined the minimal pop-
ulation size before outgrowth of resistant genotypes occurred.
In Fig. 6, we show for different initial population sizes and
mutation rates and a fixed efficiency of compensation and
treatment efficiency at which minimal eR and maximal cR the
resistance-compensated genotype can emerge. With larger ini-
tial population sizes, it is likely that the R genotype is already
FIG. 4. RC fitness in the presence of treatment and extinction. In
order to escape extinction during treatment, the fitness of the RC
genotype needs to be above a certain threshold. This plot shows the
maximal cost of resistance for a given eR and cR that permits long-term
survival of the RC genotype. It was created by solving rwRC  d for cR,
yielding cR  1/(1  eC,drug)  d/[r(1  a  aeR)(1  eC,drug)] as the
condition for the bacteria to persist. The antimicrobial activity (a) has
a value of 1.
FIG. 5. Fitness of R and RC genotypes and minimal population
size during treatment. In this plot, the color scale indicates the minimal
population sizes during treatment for different cR and eC,drug values
upon treatment initiation in a naive bacterial population of 107 organ-
isms. The area in which the growth rate of the RC genotype is smaller
than the death rate (i.e., where extinction is inevitable) is shaded in
gray. The dashed lines represent fitness isoclines for the RC genotype.
Other parameters take the following values: a  1, cC  0.1, cR  0.2,
eR  0.9, eC,drug  0.6, and 3  10
8.
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present. To account for this, we compared the initially homo-
geneous population (dashed lines) to a population that ex-
panded from 103 wild-type cells to the population size at which
treatment commenced (solid lines). We considered emergence
of the resistant genotypes successful if the minimal total pop-
ulation size during the process of emergence did not fall below
one cell. When the initial population size and/or mutation rate
was low, the generation of resistant organisms was too slow to
generate the RC genotype before extinction. In this case, sur-
vival seemed to depend mainly on the fitness of the R geno-
type. When the generation of new genotypes was fast and the
efficiency of the resistance mutation was high, high costs of
resistance did not lead to extinction, as they could be compen-
sated.
The model used here is deterministic, and therefore frac-
tions of resistant cells may give rise to new mutants. As a
comparison, we also calculated the probability P(no mutation)
that the population of initially present R cells would become
extinct before the RC genotype could be generated. This prob-
ability is given by e
NR,03
dwR,1r (45), with NR,0 denoting the initial
size of the R subpopulation. The number of resistant cells in
the beginning is given by the mutation-selection balance
N03
cRd
(N0 is the initial total population size), such that P(no muta-
tion) becomes e
N033
cRddwR,1r. If we assume a fixed number x of
compensatory loci for each resistance mutation (i.e., x3 
3), then the mutation rate greatly influences this probability,
as P(no mutation) depends on the square of the overall muta-
tion rate. We illustrate this in Fig. 7. With lower mutation
rates, the RC genotype could emerge only when the R ge-
notype alone was viable (compare to Fig. 4), while the proba-
bility of RC emergence became independent of R fitness at
mutation rates of 105. The emergence of the RC genotype
does not secure survival, as this genotype also has to be viable
during treatment. The results obtained with the three versions
of our model and the calculation of the probability that
resistant compensated cells will emerge correspond well.
Therefore, our findings that the initial population size and,
especially, the mutation rate determine whether a pathogen
population may survive treatment at a given fitness of resis-
tant cells appear to be robust.
(ii) Discontinuation of treatment and reversion. After dis-
continuing treatment, resistance may persist or reversion to the
wild-type genotype may occur. As mentioned in the introduc-
tion, both outcomes have been reported, although theoretical
models predict that reversion is unlikely or is a very slow
process. This gives rise to the question of which factors deter-
mine whether reversion or compensation will take place, and if
so, when it will occur. With our model, we are able to investi-
gate the effects of different fitness gains, possible fitness valleys,
FIG. 6. Mutation rate, population size, and extinction during treatment. These graphs show the minimal cR for which a bacterial population
goes extinct for a given eR. Extinction is defined to occur when the total population size drops below 1 during antimicrobial therapy. The area in
which the growth rate of the RC genotype is smaller than the death rate (i.e., where extinction is inevitable) is shaded in gray. The dashed lines
correspond to an initially homogeneous wild-type population, while the solid lines correspond to a population that expanded from 103 cells to the
population size at which treatment commenced. (A) Various initial population sizes (N0). (B) Various mutation rates (3). Unless varied,
parameters take the following values: a  1, cC  0.1, cR  0.2, eR  0.9, eC,drug  0.6, 3  10
8, and N0  10
7.
FIG. 7. Probability of generating RC bacteria before R extinc-
tion. This graph shows for which maximal eR the probability that the
R population becomes extinct before creating an RC genotype is
larger than 95%. It was created by solving e
N033
cRddwR,1r  0.95 for eR,
yielding eR 
N033 d2cRln(0.95)
cRdr1  cRln(0.95)
for a  1. The values of 3 are
given next to the corresponding curves. For mutation rates of104.25,
the RC genotype could always emerge. N0  10
7, 3  103.
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and different mutation rates at the respective loci, which could
be interpreted as differences in the sizes of mutational targets.
When we describe a homogeneous population of resistant
bacteria in a constant environment with a logistic equation
without a death rate, the population size (nR) will increase
until the carrying capacity is reached, at which point bacterial
growth ceases. At the carrying capacity, no invasion of a dif-
ferent genotype is possible in the case of a growth-dependent
mutation rate, and invasion is very slow when the new genotype
is generated only by mutation and the mutant does not grow.
When a bacterial kill rate is included, which is biologically
more plausible, the population will not grow to the carrying
capacity, but to a lower density that depends on the kill rate.
If we neglect the mutation rates, as they are very small com-
pared to the growth and kill rates, the steady-state value is
given by nˆR  K1  drwR (also see reference 36). An
invasion of the wild-type strain (n) is now possible when
wd
wR
 d, i.e., the fitness of the invading strain, is larger than
that of the residing strain and the kill rate is larger than zero.
We therefore first investigated the effects of the relative
fitness of the RC genotype and the relative kill rate (i.e., the
kill rate d relative to the growth rate r) on the time to reversion.
Reversion was defined as95% of the population consisting of
wild-type cells. For most kill rates and/or fitness values of the
R or RC genotype, reversion took place within a few days
(Fig. 8). The time to reversion increased with increasing fitness
of the RC genotype and decreasing kill rate, but reversion
always took place unless the relative kill rate was zero or
compensation in the absence of treatment was perfect
(wRC,0  1). The time to reversion increased slightly with a
decreasing overall mutation rate, but unexpectedly, the ratio
of 4 to 3 had very little effect (see Fig. S4 in the sup-
plemental material). Although our model consists of only
two loci, we could interpret those as multiple equivalent loci
that are combined into one. The forward mutation rates 3
and 3 could then be calculated by assuming a fixed mutation
rate per locus (corresponding to 4 and 4) multiplied by the
number of possible loci. At lower fitness values of the R
genotype, the back mutation rates 4 and 4, which could be
interpreted as mutation rates per locus, determined when re-
version to the ancestral susceptible genotype took place. Only
when the R genotype was nearly as fit as the wild type did the
ratios of 3 to 4 and 3 to 4 influence time to reversion.
The value of 3 seemed to be less important, as the two curves
with the same 3 values coincided. Taken together, the rela-
tive fitness of the RC genotype (and thus eC,no drug) as well as
the relative kill rate had the largest effect on the time until
reversion occurred.
(iii) Repeated treatment courses and reversion. As shown
above, reversibility depended on the efficiency of compensa-
tion in a drug-free environment (eC,no drug), and we expect this
reversibility to determine the success of any subsequent ther-
apy. We therefore investigated the effect of the length of treat-
ment fluctuation on the fraction of resistant cells within bac-
terial populations that had different types of compensatory
mutations. If compensation in the absence of antibiotics was
not perfect, reversion took place repeatedly (see Fig. S5 in the
supplemental material). As a result, the average long-term
population size and composition of the population in a fluctu-
ating environment depended on the fluctuation period (see
Fig. S6 in the supplemental material). The relationships be-
tween period length and total population size, size of the re-
sistant subpopulation, and fraction of resistant cells were not
monotonic and differed depending on the exact fitness values
of the possible genotypes. Furthermore, there was no apparent
correlation between total population size, the size of the resis-
tant subpopulation, and the fraction of resistant cells. Each of
these three measures was minimal at intermediate period
lengths for some fitness values (see Fig. S7 in the supplemental
material). In some cases (see Fig. S6A and C in the supple-
mental material), the fraction of resistant or resistant compen-
sated cells declined before the overall population size rose.
This shows that the abundance of resistant strains depends not
only on overall antibiotic consumption but also on the fitness
of the possible genotypes in both environments. Also, it shows
FIG. 8. Reversion to susceptibility after cessation of treatment and relative to kill rate. In this figure, we show how the fitness of the RC
genotype and the bacterial kill rate relative to the growth rate influence reversion to susceptibility. The initial population consisted of 109
bacteria of the R (A) or the RC (B) genotype. The x axis (horizontal) shows the relative kill rate, i.e., the kill rate divided by the growth
rate, and the y axis shows the efficiency of compensation, and thus RC fitness relative to that of the wild type. On the z axis are the numbers
of days until 95% of the population consisted of the wild-type genotype. Other parameters take the following values: a  1, eR  1, cR 
0.5, cC  0.5, eR  1, 3  10
8, and N0  10
9.
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that the population dynamics during repeated treatment
courses depend on the type of compensation, as we would have
expected (Fig. 2).
DISCUSSION
In the context of antibiotic resistance, a compensatory mu-
tation can be defined as a mutation that alleviates the fitness
costs of a resistance mutation but does not in itself increase the
antibiotic tolerance of a microbe. To unambiguously classify a
mutation as compensatory, we therefore need to determine the
fitness of strains of four genotypes, i.e., the wild type, resis-
tance, compensated, and resistant-compensated genotypes, in
both the absence and presence of treatment. If the fitness of
the C genotype is not measured, it remains unclear whether
the potential compensatory mutation is beneficial irrespective
of the genetic background. It is also important to measure C
fitness under antibiotic selection pressure, as the mutation may
be an additional resistance mutation. Although there is a large
body of literature describing the amelioration of the costs of
antibacterial resistance, to our knowledge there is no study
measuring the replicative fitness of all four genotypes in both
the absence and presence of treatment. If the underlying bio-
logical mechanisms of the fitness increase upon acquisition of
a mutation do not indicate compensation, it remains uncertain
whether the described mutations are indeed compensatory mu-
tations. Judging from the two studies comparing compensation
in the absence and presence of antibiotic selection pressure,
there is also no evidence for a simple relationship between the
fitness increase in the two environments upon acquisition of a
compensatory mutation (63, 67) (Fig. 3).
The main aim of this study was to obtain a better conceptual
understanding of how compensatory mutations affect bacterial
fitness and how this—combined with other factors—deter-
mines reversibility and treatment success for both single and
repeated treatment courses. In order to illustrate and validate
our parameterization of fitness values, we developed a delib-
erately simple mathematical model that focuses on the fitness
gains in the absence and presence of treatment. This very
simple theoretical framework has correspondingly many limi-
tations. Our model is based on deterministic equations that
assume an infinite population size and therefore does not in-
clude bottlenecks. It is thus more applicable to large popula-
tion sizes such as those, e.g., in the microflora, which may be
the source of recurrent infections. Moreover, we considered
only two loci and only one drug concentration. Resistance is
often acquired by multiple mutations (3, 5), compensation may
take place first in one and then in another environment, and
even in the same environment, fitness costs may be amelio-
rated in a stepwise manner (72). Yet given our very limited
knowledge about the fitness values of resistant compensated
bacteria, a simple framework for which we can find reliable
parameters is preferable to a more complex model.
The model presented here describes the logistic growth of a
bacterial population with the four potential genotypes by use
of a first-order bacterial death rate. Estimates of the bacterial
growth rate, carrying capacity, and death rate were derived
from publications describing in vivo bacterial growth (26, 27,
59, 65, 80). The individual fitness of a genotype can be incor-
porated in two ways: either fitness correlates positively with the
growth rate, or there is an inverse correlation with the kill rate.
The former would correspond to differences in replicative fit-
ness between the genotypes, the latter, for example, to differ-
ences in immune recognition. Although the R genotype and,
more often, the RC genotype may be more fit than the wild
type (48, 67), we considered here only fitness values that were
smaller than or equal to those of the wild type.
We also assume that the rate of emergence of new strains is
a first-order process that depends only on the abundance of the
ancestral genotype. Therefore, these models describe the rise
of mutants in a sufficiently large population and resistance
acquired by mutation rather than by horizontal transfer. Fi-
nally, in the first and second versions of the model, the anti-
microbial activity does not increase the kill rate but suppresses
bacterial growth, so this model describes bacteriostatic rather
than bactericidal therapy. Conversely, the third version of the
model describes bactericidal treatment. Although bacteriosta-
tic or bactericidal action is not an intrinsic property of antibi-
otics but is influenced by drug concentration and the targeted
pathogen, beta-lactams, fluoroquinolones, and aminoglyco-
sides are usually regarded as bactericidal (18, 38, 55, 77),
whereas chloramphenicol is regarded as bacteriostatic (30).
Therefore, the appropriate version of the model might be used
to describe these compounds.
Using both the models where bacterial growth was propor-
tional to fitness and that where fitness correlated inversely with
the kill rate, we investigated under which conditions bacteria
can survive long-term antibiotic therapy. In model 1 and model
3, where mutation rates are independent of growth, the results
were exactly the same. Due to the growth dependence of mu-
tation in the second model, it is difficult to adjust the mutation
rate such that the overall generation of mutations remains the
same as in the other two models. Nevertheless, the results were
qualitatively the same for all three models and were very in-
tuitive: a potential resistance mutation has to be more efficient
in suppressing the effect of treatment when it is accompanied
by higher costs. Compensation of the costs, on the other hand,
allows bacterial survival at a higher cost and lower efficiency of
resistance mutations. Also, our results show that the conditions
for clearing an infection depend on the kill rate, which could be
interpreted as the action of an immune system, as well as on
the antimicrobial activity of the drug. The higher the kill rate
and the more powerful the treatment, the less costly and more
efficient a resistance mutation has to be to allow survival. This
agrees with the findings that Mycobacterium tuberculosis strains
of low fitness are able to spread among HIV-infected patients
(76) and that exposure to low antibiotic doses selects for car-
riage of resistant strains (28). A higher mutation rate and
larger initial population size led to a faster generation of R
and RC genotypes and thus determined how fit a potential
resistance mutation had to be to allow the population to escape
extinction. A positive correlation between resistance and mu-
tation rate has also been found experimentally and theoreti-
cally (e.g., see references 25 and 40; reviewed in reference 53).
Our deterministic model certainly underestimates extinction
and overestimates the rise of resistant mutants, as fractions of
cells may still generate new mutants. This is especially true for
cases where the product of the initial population size and the
mutation rate is smaller than 1 (45). Thus, the predictions
concerning treatment success may be rather pessimistic. On
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the other hand, they may be too optimistic when the bacterial
population is already large when treatment is started, because
antibiotics may be less effective then (17, 78). Nevertheless, the
obtained qualitative findings correspond to both the findings
from calculating the probability of generating RC mutants and
well-known results (“hit hard and hit early”) and therefore
validate our model.
Decreasing levels of resistance upon antibiotic restriction
have been reported in several epidemiological studies (e.g., see
reference 62). Especially in hospital settings with a typically
high turnover in the patient population, these findings could be
explained by clonal shifts where resistant strains may be “washed
out” even without having a fitness disadvantage compared to the
replacing susceptible strains (2, 42). In contrast, genetic reversion
is expected to be unlikely and, if it occurs, very slow (13, 42), also
because of the accumulation of compensatory mutations. Yet the
argument that the resistant-compensated genotype is easily
reached by selection but difficult to leave is strictly valid only if we
assume that a compensatory mutation is advantageous in both
the absence and presence of treatment (Fig. 2). As we have
seen (Fig. 3), this is not necessarily the case. Levin et al. (43)
argued that the effective mutation rate toward compensation is
often higher than the rate of converting back to the wild type,
such that a resistant population may compensate for the fitness
loss in the absence of antibiotics faster than reverting. In the
same study, it was also argued that bottlenecks arising from
transmission events or serial passage in vitro additionally en-
rich the genotype with the faster initial emergence. Again, we
would expect this phenomenon only if the compensatory mu-
tation conferred an advantage (or not a substantial disadvan-
tage) in both environments. Even if this was the case, the ratio
of the mutation rate of reverting back from resistance (4) to
the mutation rate of acquiring compensation (3) had a neg-
ligible effect on the time to reversion in our model. Bacteria
that are part of the microflora and may cause endogenous
infections might face bottlenecks only infrequently, such that
the model presented here may be more applicable. Although
both persistence and disappearance of resistant and resistant
compensated bacteria in the gut microflora have been reported
(e.g., see references 21, 47, and 75), the pathogens in the
majority of clinical studies that reported reversion were part of
the normal human microflora (16, 29, 33, 56, 57, 70). Although
this remains to be investigated fully, the diverging theoretical
predictions from the model presented here and the one by
Levin et al. (43) are likely due to the absence of serial bottle-
necks in our models.
We always found reversion if the fitness of the resistance-
compensated genotype was lower than that of the wild type and
if there was bacterial death, i.e., the kill rate was nonzero.
Constant bacterial populations seem to represent a steady-
state situation with a balance of growth and death rather than
a situation of complete growth arrest (23).
According to our model, we would expect reversion when-
ever the resistant genotypes either have a growth disadvantage
or are killed more easily. Indeed, Gustafsson et al. reported
reversion of Staphylococcus epidermis on human skin within 10
to 30 days when resistance was costly but persistence of strains
carrying no-cost resistance mutations (29). The importance of
the bacterial kill rate is further supported by the observation
that reversion occurred more frequently in mice than in bac-
teria grown in vitro (12), possibly due to a strong immune
reaction in the mice (58). Furthermore, our finding is corrob-
orated by theoretical studies showing that reversion occurred if
the resistant-compensated genotype had a low relative fitness
(36) and that immune responses may prohibit the growth of
less-fit resistant bacteria (31).
The times to reversion which we observed in our model are
compatible with the time frames reported in clinical studies
(29, 33, 57, 70) (see Fig. S1 in the supplemental material).
Reversion was extremely slow with high RC fitness and/or a
low kill rate (in the range of years for our parameterization), so
it is not surprising that reversion was rarely observed under
laboratory conditions. Saager et al. (70) and Meka et al. (57)
studied clonally related strains within single patients and found
reversion of linezolid resistance after 4 months in vancomycin-
resistant enterococci and after 7 months in methicillin-resistant
Staphylococcus aureus (MRSA). Loss of resistance to several
antibiotics within a few weeks to months was described in a
detailed case report of an elderly patient with recurrent MRSA
infections (33) (see Fig. S1 in the supplemental material). Most
importantly, bacteria became resistant to one of the antibiotics
used, but after the loss of this resistance, the same antibiotic
was used to clear the infection.
Taken together, the data obtained with our model predict
that the fitness levels of all involved genotypes in both the
absence and presence of treatment determine the emergence
and long-term abundance of resistance and that different types
of compensatory mutations lead to different dynamics during
repeated treatment courses. This prediction could be tested by
subjecting strains with different types of compensatory muta-
tions to repeated treatment courses of different lengths. We
would also expect that a higher mutation rate or a larger
population size would allow for the emergence of less-fit re-
sistant mutants. To test this, the fitness levels of resistant mu-
tants arising from populations of different sizes, perhaps car-
rying mutator genes, could be compared. Furthermore, our
model predicts that a higher turnover or kill rate accelerates
reversion, which may be addressed experimentally in chemo-
stats by varying the flow rate. Our study highlights that in order
to make quantitative predictions of antibiotic resistance evo-
lution—and indeed, in order to unambiguously identify com-
pensatory mutations—it is pertinent to measure the fitness of
all bacterial genotypes involved in both the presence and ab-
sence of antibiotic treatment.
ACKNOWLEDGMENTS
We thank Wilhelm Paulander and Dan Andersson for providing us
with the experimental data from reference 63. We also thank the
referees for helpful comments as well as So¨ren Abel for a critical
reading of the manuscript and Roger Kouyos for feedback on calcu-
lating the probability of generating RC mutants.
REFERENCES
1. Alekshun, M. N., and S. B. Levy. 2007. Molecular mechanisms of antibac-
terial multidrug resistance. Cell 128:1037–1050.
2. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Curr.
Opin. Microbiol. 6:452–456.
3. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance:
any practical conclusions? Curr. Opin. Microbiol. 9:461–465.
4. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic
resistance. Curr. Opin. Microbiol. 2:489–493.
5. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and
vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect.
12(Suppl. 1):16–23.
VOL. 54, 2010 COMPENSATION OF FITNESS COSTS OF ANTIBIOTIC RESISTANCE 2093
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
6. Baldwin, C., and B. Berkhout. 2007. HIV-1 drug-resistance and drug-depen-
dence. Retrovirology 4:78.
7. Baptista, M., F. Depardieu, P. Reynolds, P. Courvalin, and M. Arthur. 1997.
Mutations leading to increased levels of resistance to glycopeptide antibiot-
ics in VanB-type enterococci. Mol. Microbiol. 25:93–105.
8. Bergstrom, C. T., and M. Feldgarden. 2008. The ecology and evolution of
antibiotic-resistant bacteria, p. 125–137. In S. C. Stearns and J. C. Koella
(ed.), Evolution in health and disease. Oxford University Press, New York,
NY.
9. Besier, S., A. Ludwig, V. Brade, and T. A. Wichelhaus. 2005. Compensatory
adaptation to the loss of biological fitness associated with acquisition of
fusidic acid resistance in Staphylococcus aureus. Antimicrob. Agents Che-
mother. 49:1426–1431.
10. Bjorkholm, B., M. Sjolund, P. G. Falk, O. G. Berg, L. Engstrand, and D. I.
Andersson. 2001. Mutation frequency and biological cost of antibiotic resis-
tance in Helicobacter pylori. Proc. Natl. Acad. Sci. U. S. A. 98:14607–14612.
11. Bjorkman, J., D. Hughes, and D. I. Andersson. 1998. Virulence of antibiotic-
resistant Salmonella Typhimurium. Proc. Natl. Acad. Sci. U. S. A. 95:3949–
3953.
12. Bjorkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000.
Effects of environment on compensatory mutations to ameliorate costs of
antibiotic resistance. Science 287:1479–1482.
13. Bonhoeffer, S., M. Lipsitch, and B. R. Levin. 1997. Evaluating treatment
protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A.
94:12106–12111.
14. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human
immunodeficiency virus type 1 to protease inhibitors: selection of resistance
mutations in the presence and absence of the drug. J. Gen. Virol. 77:419–
426.
15. Bottger, E. C., and B. Springer. 2008. Tuberculosis: drug resistance, fitness,
and strategies for global control. Eur. J. Pediatr. 167:141–148.
16. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of
the glycopeptide resistance phenotype in Staphylococcus aureus clinical iso-
lates. Antimicrob. Agents Chemother. 44:272–277.
17. Bulitta, J. B., N. S. Ly, J. C. Yang, A. Forrest, W. J. Jusko, and B. T. Tsuji.
2009. Development and qualification of a pharmacodynamic model for the
pronounced inoculum effect of ceftazidime against Pseudomonas aerugi-
nosa. Antimicrob. Agents Chemother. 53:46–56.
18. Campion, J. J., P. J. McNamara, and M. E. Evans. 2005. Pharmacodynamic
modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob.
Agents Chemother. 49:209–219.
19. Cirz, R. T., J. K. Chin, D. R. Andes, V. de Crecy-Lagard, W. A. Craig, and
F. E. Romesberg. 2005. Inhibition of mutation and combating the evolution
of antibiotic resistance. PLoS Biol. 3:e176.
20. Cowen, L. E., L. M. Kohn, and J. B. Anderson. 2001. Divergence in fitness
and evolution of drug resistance in experimental populations of Candida
albicans. J. Bacteriol. 183:2971–2978.
21. Dethlefsen, L., S. Huse, M. L. Sogin, and D. A. Relman. 2008. The pervasive
effects of an antibiotic on the human gut microbiota, as revealed by deep 16S
rRNA sequencing. PLoS Biol. 6:e280.
22. Fernebro, J., C. Blomberg, E. Morfeldt, H. Wolf-Watz, S. Normark, and
B. H. Normark. 2008. The influence of in vitro fitness defects on pneumo-
coccal ability to colonize and to cause invasive disease. BMC Microbiol. 8:65.
23. Finkel, S. E. 2006. Long-term survival during stationary phase: evolution and
the GASP phenotype. Nat. Rev. Microbiol. 4:113–120.
24. Fraimow, H. S., and D. L. Jungkind. 1995. Vancomycin-dependent entero-
cocci: a clinical and laboratory assessment. Adv. Exp. Med. Biol. 390:97–107.
25. Gerrish, P. J., and J. G. Garcia-Lerma. 2003. Mutation rate and the efficacy
of antimicrobial drug treatment. Lancet Infect. Dis. 3:28–32.
26. Grant, A. J., O. Restif, T. J. McKinley, M. Sheppard, D. J. Maskell, and P.
Mastroeni. 2008. Modelling within-host spatiotemporal dynamics of invasive
bacterial disease. PLoS Biol. 6:e74.
27. Griffith, D., and M. N. Dudley. 2007. Animal models of infection for the
study of antibiotic pharmacodynamics, p. 79–102. In C. H. Nightingale, P. G.
Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmaco-
dynamics in theory and clinical practice. CRC Press, Boca Raton, FL.
28. Guillemot, D., C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-
Kervroedan, G. Bouvenot, and E. Eschwege. 1998. Low dosage and long
treatment duration of beta-lactam: risk factors for carriage of penicillin-
resistant Streptococcus pneumoniae. JAMA 279:365–370.
29. Gustafsson, I., O. Cars, and D. I. Andersson. 2003. Fitness of antibiotic
resistant Staphylococcus epidermidis assessed by competition on the skin of
human volunteers. J. Antimicrob. Chemother. 52:258–263.
30. Hancock, R. E. 2005. Mechanisms of action of newer antibiotics for Gram-
positive pathogens. Lancet Infect. Dis. 5:209–218.
31. Handel, A., E. Margolis, and B. R. Levin. 2009. Exploring the role of the
immune response in preventing antibiotic resistance. J. Theor. Biol. 256:655–
662.
32. Handel, A., R. R. Regoes, and R. Antia. 2006. The role of compensatory
mutations in the emergence of drug resistance. PLoS Comput. Biol. 2:e137.
33. Huang, T. D., C. Almpanis, O. Denis, C. Nonhoff, B. Delaere, and Y. Glupc-
zynski. 2007. Reversion of resistance in relapsing infection caused by a
glycopeptide-intermediate methicillin-resistant Staphylococcus aureus iso-
late. Eur. J. Clin. Microbiol. Infect. Dis. 26:419–422.
34. Hurdle, J. G., A. J. O’Neill, E. Ingham, C. Fishwick, and I. Chopra. 2004.
Analysis of mupirocin resistance and fitness in Staphylococcus aureus by
molecular genetic and structural modeling techniques. Antimicrob. Agents
Chemother. 48:4366–4376.
35. Ihaka, R., and R. Gentleman. 1996. R: a language for data analysis and
graphics. J. Comput. Graph. Stat. 5:299–314.
36. Jeger, M. J., P. J. Wijngaarden, and R. F. Hoekstra. 2008. Adaptation to the
cost of resistance in a haploid clonally reproducing organism: the role of
mutation, migration and selection. J. Theor. Biol. 252:621–632.
37. Jiang, H., J. J. Patel, M. Yi, J. Mu, J. Ding, R. Stephens, R. A. Cooper, M. T.
Ferdig, and X. Z. Su. 2008. Genome-wide compensatory changes accompany
drug-selected mutations in the Plasmodium falciparum crt gene. PLoS One
3:e2484.
38. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bach-
hawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and
G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo
amplification of antibiotic-resistant bacterial populations during therapy.
J. Clin. Invest. 112:275–285.
39. Kimura, M. 1990. Some models of neutral evolution, compensatory evolu-
tion, and the shifting balance process. Theor. Popul. Biol. 37:150–158.
40. Komp Lindgren, P., A. Karlsson, and D. Hughes. 2003. Mutation rate and
evolution of fluoroquinolone resistance in Escherichia coli isolates from
patients with urinary tract infections. Antimicrob. Agents Chemother. 47:
3222–3232.
41. Kondo, N., K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki,
and K. Hiramatsu. 2001. Eagle-type methicillin resistance: new phenotype of
high methicillin resistance under mec regulator gene control. Antimicrob.
Agents Chemother. 45:815–824.
42. Levin, B. R. 2001. Minimizing potential resistance: a population dynamics
view. Clin. Infect. Dis. 33(Suppl. 3):S161–S169.
43. Levin, B. R., V. Perrot, and N. Walker. 2000. Compensatory mutations,
antibiotic resistance and the population genetics of adaptive evolution in
bacteria. Genetics 154:985–997.
44. Lipsitch, M. 2001. The rise and fall of antimicrobial resistance. Trends
Microbiol. 9:438–444.
45. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicro-
bial chemotherapy. Antimicrob. Agents Chemother. 41:363–373.
46. Loewe, L., V. Textor, and S. Scherer. 2003. High deleterious genomic mu-
tation rate in stationary phase of Escherichia coli. Science 302:1558–1560.
47. Lofmark, S., C. Jernberg, H. Billstrom, D. I. Andersson, and C. Edlund.
2008. Restored fitness leads to long-term persistence of resistant Bacteroides
strains in the human intestine. Anaerobe 14:157–160.
48. Luo, N., S. Pereira, O. Sahin, J. Lin, S. Huang, L. Michel, and Q. Zhang.
2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter
jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci.
U. S. A. 102:541–546.
49. Ma, C., J. Tran, C. Li, L. Ganesan, D. Wood, and N. Morrissette. 2008.
Secondary mutations correct fitness defects in Toxoplasma gondii with dini-
troaniline resistance mutations. Genetics 180:845–856.
50. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the deleterious
effects of antimicrobial drug resistance mutations by compensatory evolu-
tion. Res. Microbiol. 155:360–369.
51. Majcherczyk, P. A., J. L. Barblan, P. Moreillon, and J. M. Entenza. 2008.
Development of glycopeptide-intermediate resistance by Staphylococcus au-
reus leads to attenuated infectivity in a rat model of endocarditis. Microb.
Pathog. 45:408–414.
52. Marcusson, L. L., N. Frimodt-Moller, and D. Hughes. 2009. Interplay in the
selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog.
5:e1000541.
53. Martinez, J. L., and F. Baquero. 2000. Mutation frequencies and antibiotic
resistance. Antimicrob. Agents Chemother. 44:1771–1777.
54. May, R. M. 1976. Simple mathematical models with very complicated dy-
namics. Nature 261:459–467.
55. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004.
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes
with an extended-release formulation of ciprofloxacin. Antimicrob. Agents
Chemother. 48:2061–2068.
56. Meka, V. G., H. S. Gold, A. Cooke, L. Venkataraman, G. M. Eliopoulos, R. C.
Moellering, Jr., and S. G. Jenkins. 2004. Reversion to susceptibility in a
linezolid-resistant clinical isolate of Staphylococcus aureus. J. Antimicrob.
Chemother. 54:818–820.
57. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman,
P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold.
2004. Linezolid resistance in sequential Staphylococcus aureus isolates as-
sociated with a T2500A mutation in the 23S rRNA gene and loss of a single
copy of rRNA. J. Infect. Dis. 190:311–317.
58. Na, H. S., H. J. Kim, H. C. Lee, Y. Hong, J. H. Rhee, and H. E. Choy. 2006.
Immune response induced by Salmonella typhimurium defective in ppGpp
synthesis. Vaccine 24:2027–2034.
59. Needham, A. J., M. Kibart, H. Crossley, P. W. Ingham, and S. J. Foster.
2094 SCHULZ ZUR WIESCH ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
2004. Drosophila melanogaster as a model host for Staphylococcus aureus
infection. Microbiology 150:2347–2355.
60. Nijhuis, M., S. Deeks, and C. Boucher. 2001. Implications of antiretroviral
resistance on viral fitness. Curr. Opin. Infect. Dis. 14:23–28.
61. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen,
H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E.
Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 blood-
stream Candida isolates in the United States. Antimicrob. Agents Che-
mother. 47:3149–3154.
62. Pakyz, A. L., M. Oinonen, and R. E. Polk. 2009. Relationship of carbapenem
restriction in 22 university teaching hospitals to carbapenem use and car-
bapenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Che-
mother. 53:1983–1986.
63. Paulander, W., S. Maisnier-Patin, and D. I. Andersson. 2007. Multiple
mechanisms to ameliorate the fitness burden of mupirocin resistance in
Salmonella typhimurium. Mol. Microbiol. 64:1038–1048.
64. Perichon, B., and P. Courvalin. 2009. VanA-type vancomycin-resistant
Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4580–4587.
65. Peters, R. P., M. A. van Agtmael, S. Gierveld, S. A. Danner, A. B. Groeneveld,
C. M. Vandenbroucke-Grauls, and P. H. Savelkoul. 2007. Quantitative de-
tection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to
diagnose bacteremia in patients in the intensive care unit. J. Clin. Microbiol.
45:3641–3646.
66. Randall, L. P., M. C. Bagnall, K. A. Karatzas, N. C. Coldham, L. J. Piddock,
and M. J. Woodward. 2008. Fitness and dissemination of disinfectant-se-
lected multiple-antibiotic-resistant (MAR) strains of Salmonella enterica
serovar Typhimurium in chickens. J. Antimicrob. Chemother. 61:156–162.
67. Reynolds, M. G. 2000. Compensatory evolution in rifampin-resistant Esch-
erichia coli. Genetics 156:1471–1481.
68. Rozen, D. E., L. McGee, B. R. Levin, and K. P. Klugman. 2007. Fitness costs
of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob.
Agents Chemother. 51:412–416.
69. Ruusala, T., D. Andersson, M. Ehrenberg, and C. G. Kurland. 1984. Hyper-
accurate ribosomes inhibit growth. EMBO J. 3:2575–2580.
70. Saager, B., H. Rohde, B. S. Timmerbeil, G. Franke, W. Pothmann, J. Dahlke,
S. Scherpe, I. Sobottka, P. Heisig, and M. A. Horstkotte. 2008. Molecular
characterisation of linezolid resistance in two vancomycin-resistant (VanB)
Enterococcus faecium isolates using pyrosequencing. Eur. J. Clin. Microbiol.
Infect. Dis. 27:873–878.
71. San Millan, A., F. Depardieu, S. Godreuil, and P. Courvalin. 2009. VanB-
type Enterococcus faecium clinical isolate successively inducibly resistant to,
dependent on, and constitutively resistant to vancomycin. Antimicrob.
Agents Chemother. 53:1974–1982.
72. Schoustra, S. E., A. J. Debets, M. Slakhorst, and R. F. Hoekstra. 2006.
Reducing the cost of resistance; experimental evolution in the filamentous
fungus Aspergillus nidulans. J. Evol. Biol. 19:1115–1127.
73. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness costs
of antibiotic resistance in Escherichia coli. Proc. Biol. Sci. 264:1287–1291.
74. Sniegowski, P. 2004. Evolution: bacterial mutation in stationary phase. Curr.
Biol. 14:R245–R246.
75. Sommer, M. O., G. Dantas, and G. M. Church. 2009. Functional character-
ization of the antibiotic resistance reservoir in the human microflora. Science
325:1128–1131.
76. Strauss, O. J., R. M. Warren, A. Jordaan, E. M. Streicher, M. Hanekom,
A. A. Falmer, H. Albert, A. Trollip, E. Hoosain, P. D. van Helden, and T. C.
Victor. 2008. Spread of a low-fitness drug-resistant Mycobacterium tubercu-
losis strain in a setting of high human immunodeficiency virus prevalence.
J. Clin. Microbiol. 46:1514–1516.
77. Tam, V. H., S. Kabbara, G. Vo, A. N. Schilling, and E. A. Coyle. 2006.
Comparative pharmacodynamics of gentamicin against Staphylococcus
aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:
2626–2631.
78. Udekwu, K. I., N. Parrish, P. Ankomah, F. Baquero, and B. R. Levin. 2009.
Functional relationship between bacterial cell density and the efficacy of
antibiotics. J. Antimicrob. Chemother. 63:745–757.
79. Van Bambeke, F., M. Chauvel, P. E. Reynolds, H. S. Fraimow, and P.
Courvalin. 1999. Vancomycin-dependent Enterococcus faecalis clinical iso-
lates and revertant mutants. Antimicrob. Agents Chemother. 43:41–47.
80. Wilson, M. L., and L. Gaido. 2004. Laboratory diagnosis of urinary tract
infections in adult patients. Clin. Infect. Dis. 38:1150–1158.
81. Wolter, N., A. M. Smith, D. J. Farrell, and K. P. Klugman. 2006. Hetero-
geneous macrolide resistance and gene conversion in the pneumococcus.
Antimicrob. Agents Chemother. 50:359–361.
82. World Health Organization, T. Prentice, and L. Tucker Reinders. 2007. The
world health report 2007—a safer future: global public health security in the
21st century. World Health Organization, Geneva, Switzerland.
83. Wright, S. 1982. The shifting balance theory and macroevolution. Annu.
Rev. Genet. 16:1–19.
84. Yeh, P. J., M. J. Hegreness, A. P. Aiden, and R. Kishony. 2009. Drug
interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol.
7:460–466.
85. Zhang, Q., O. Sahin, P. F. McDermott, and S. Payot. 2006. Fitness of
antimicrobial-resistant Campylobacter and Salmonella. Microbes Infect.
8:1972–1978.
VOL. 54, 2010 COMPENSATION OF FITNESS COSTS OF ANTIBIOTIC RESISTANCE 2095
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
